tbuckley/cabot-search huggingface dataset:
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
Authors: Mahesh Swaminathan, Hagop M. Kantarjian, Naval Daver, Gautam Borthakur, Maro Ohanian, Tapan Kadia, Courtney D. DiNardo, Nitin Jain, Zeev Estrov, Alessandra Ferrajoli, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naveen Pemmaraju, Elias J. Jabbour, William G Wierda, Farhad Ravandi, Maria Rhona Pinsoy, Jorge E. Cortes
Journal: Blood (2017)
Polypharmacy—Time to Get Beyond Numbers
Authors: Michael A. Steinman
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The NCI pediatric central institutional review board (PedCIRB) initiative: Progress and impact
Authors: B. D. Anderson, J. Goldberg, J. Adler, L. Covington, D. Olson, B. Gordon, G. Reaman, J. Everett, M. Smith, M. Christian
Journal: Journal of Clinical Oncology (2007)

6632 NCI has developed a central IRB (PedCIRB) to review NCI-sponsored pediatric clinical trials conducted by the Children's Oncology Group (COG). COG comprises ∼200 U.S. medical institutions and protocol activation traditionally requires separate protocol review by each local IRB (LIRB) and, subsequently, a review of each protocol amendment and significant adverse event. The PedCIRB model seeks to increase patient protection by improving the expertise of protocol reviewers and making their review available to all PedCIRB participating institutions. The PedCIRB consists of experts in pediatric oncology, pediatric medicine, nursing, pharmacy, bioethics, biostatistics, as well as patient advocates and childhood cancer survivors. The PedCIRB model also eliminates redundant reviews, reduces administrative burdens on local COG investigators and LIRBs, and can accelerate the pace of local protocol activation, thus increasing the availability of clinical trials to children with cancer. The PedCIRB conducts a full board protocol review that is available via a confidential website to participating LIRBs. LIRBs can choose to perform a facilitated review, using PedCIRB materials, that focuses on local concerns, rather than a full LIRB protocol review. If the LIRB accepts the PedCIRB review, the PedCIRB becomes the IRB of record for that protocol and takes responsibility for the review of subsequent protocol amendments, adverse events and continuing reviews. Since starting in November 2004, the PedCIRB has reviewed 59 protocols. Initial reviews resulted in 44 approvals pending modification and 15 protocols being tabled for further information. The time from protocol submission to final approval by the PedCIRB has ranged from 3 to 28 weeks with an average time of 16.9 weeks during year one and 12.7 weeks during year two of the project. As of November 2006, 117 of a possible 197 U.S. COG institutions (59%) have signed on to the PedCIRB initiative and 70% of the participating institutions have conducted facilitated reviews (total 750) for the 30 protocols available on the PedCIRB website. The PedCIRB's influence on protocol development and patient accrual timelines will be discussed. No significant financial relationships to disclose.
PO41A NURSE LED TELEPHONE CLINIC IMPROVES PATIENT WAITING TIMES AND EXPERIENCE
Authors: Liz Ford, Laura Mullens, Jill MacColl, Donna Moore, Vicky Hurwitz
Journal: Neuro-Oncology (2015)

INTRODUCTION: Kings College Hospital provides Neuro-oncology surgical treatment and follow up for the South East England with a catchment of 4.1 million. Much of the Clinical Nurse Specialist's (CNS) work is via telephone, predominantly direct patient contact but also providing expert advice to primary and secondary healthcare professionals. Due to clinical commitments, CNSs are often not able to take calls as they come in. Administrative staff send emails to the joint address, resulting in a high volume of email traffic, no one CNS responsible for returning calls, and poor patient satisfaction regarding response time. METHOD: In December 2013 a telephone clinic was created on PIMMS. Administrative staff book patients in for a call back, either that afternoon or on a specific day. Each CNS had an allocated clinic day and can book patients for future calls, to check the response to a medication change for example. This also captured the huge volume of work the team conducted via phone which had previously been unrecorded. RESULTS: Numbers in the telephone clinic have steadily increased in size since its inception. Some months more patients were reviewed in the telephone clinic than in either of the Neuro-oncology clinics. (N.B. Full tables and figures will be provided in the advent of a presentation). CONCLUSION: The clinic has created a reliable way of ensuring patients are given high quality support and advice over the telephone. It also captures the amount of work generated from a single call. It does not however capture the work load of calls into the office when patients are put straight through. The CNS team are aware there is gross under reporting of call volume and and are looking at ways to improve this.
Preparations and Appliances
Authors: T G ROBINSON
Journal: BMJ (1950)

REPORTS OF SOCIETIESBMEISHu-, 1005 pertussis vaccination during the time of a clearly defined epidemic of poliomyelitis, but he was hopeful that within a year or two it would be possible to continue with full confidence those immunization proceduies which were becoming essential parts of our public health measures and of our general com- munity life.
A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC)
Authors: K. Usui, A. Inoue, O. Ishimoto, M. Tanaka, S. Koinumaru, N. Matsubara, M. Kanbe, K. Gomi, Y. Saijo, T. Nukiwa
Journal: Journal of Clinical Oncology (2005)

7248 Background: Paclitaxel combined with carboplatin (PC) is a commonly used regimen in advanced NSCLC. Although some studies suggested that PC is also effective for elderly patients, weekly paclitaxel combined with carboplatin for those patients has not been reported. We conducted this phase II trial to evaluate the safety and the efficacy of weekly paclitaxel and carboplatin for elderly patients with advanced NSCLC. Methods: Patients with stage IIIB, IV or postoperative recurrent NSCLC, PS ≤ 1, ≥ 70 years old received weekly paclitaxel (70mg/m2/wk) on d1, 8, 15, and carboplatin (AUC 6) on d1. Treatment was repeated every 4 weeks. Results: From May 2002 to Aug 2004, 42 patients were enrolled: median age (range), 75 (70–81); male/female, 32/10; stage IIIB/IV/postoperative recurrence, 13/25/4. Two patients never received study drug and 40 patients were evaluable for the safety and the efficacy. ≥Grade 3 toxicities included neutropenia (70%); thrombocytopenia (15%); anemia (13%); infection (10%); fatigue and febrile neutropenia (5%). No ≥grade 3 neurotoxicity was observed. One treatment related death (infection) was observed. Overall response rate was 45%; CR=0, PR=18, SD=11, PD=7, NE=4. To date, median survival time was 13 months and the 1-year survival rate was 58%. Conclusion: These results suggest that weekly paclitaxel and carboplatin is comparable to standard PC in efficacy and seems to be safer than standard PC. We are now conducting a randomized trial that compare weekly paclitaxel and carboplatin to standard PC. No significant financial relationships to disclose.
Respiratory sections of questionnaires are imprecise
Authors: R. Clifford
Journal: BMJ (1996)

EDITOR,—The national child development study is a source of abundant but often inaccurate data that is all too tempting for paper generators. Unfortunately, the respiratory sections of the questionnaires used in the study are so imprecise as to be almost worthless. Diagnoses rather than symptoms predominate and are thus open to error. Questions have differed considerably with each …
Magnetic Resonance and Ultrasound Image Fusion Supported Transperineal Prostate Biopsy Using the Ginsburg Protocol: Technique, Learning Points, and Biopsy Results
Authors: Nienke Hansen, Giulio Patruno, Karan Wadhwa, Gabriele Gaziev, Roberto Miano, Tristan Barrett, Vincent Gnanapragasam, Andrew Doble, Anne Warren, Ola Bratt, Christof Kastner
Journal: European Urology (2016)
Sexual medicine
Authors: M Thomas, S. Rowlands, S. Randall, P. Kell, W. Dinsmore
Journal: BMJ (1997)

<h3>Background</h3> In a previous study, we concluded that a safety helmet can reduce the risk for head injury by 60%. Other studies reported similar effects, resulting in a general recommendation to wear a helmet while skiing or snowboarding. <h3>Aim</h3> To determine the effect of the expected increased helmet wear on the risk of head injury one decade after the recommendation. <h3>Methods</h3> Ski patrols reported injury cases in major Norwegian alpine ski resorts. Injury type, helmet use and other risk factors were recorded. A multiple logistic regression analysis was used to assess the relation between individual risk factors and the risk of head injuries by comparing head injured skiers (cases) with skiers and snowboarders who reported other injuries (controls). <h3>Results</h3> Helmet use was associated with improved odds for head injuries (OR: 0.45, 95% CI 0.34 to 0.60; p&lt;0.001) in 2002; this effect was attenuated in 2010 (OR: 0.79, 95% CI 0.63 to 0.98; p=0.02), and not significant in 2011 (OR: 0.80, 95% CI 0.60 to 1.06; p=0.12). For potentially severe head injuries, the protective effect of using a helmet was better sustained over the observation period, from an OR of 0.44 (95% CI 0.28 to 0.68, p&lt;0.001) in 2002 to an OR of 0.74 (95% CI 0.57 to 0.97, p=0.02) in 2010 and 0.67 (95% CI 0.47 to 0.96; p=0.03) in 2011. <h3>Conclusions</h3> We observed an unexpected reduction in the protective effect of a skiing helmet. This may be due to new skiing trends in the alpine resorts.
Abstract 56: Shifting AAV Mediated Expression Profile to Heart by an Integrated Transcriptional Targeting Strategy
Authors: Joseph E Rabinowitz, Jinhui Wang, Joshua Gorsky, Jonathan Peterson
Journal: Circulation Research (2012)

Adeno-associated viral (AAV) vectors are promising platforms for cardiac gene transport, but their broad tropism is a drawback after systematic delivery. To divert gene expression of AAV6 or 9 to heart, an integrated transcriptional targeting strategy was explored. By comparing cardiac GFP expression of scAAV6 and 9-CMV-GFP in C57/B6 or Balb/C mice, a heart-bias in C57/B6 and liver bias in Balb/C was seen. This makes the native liver biased tropism of AAV6 or 9 in Balb/C mice more suitable for the transcriptional targeting study. Luciferase (Luc) gene expression driven by cardiac specific promoters; brain natriuretic peptide (BNP), cardiac ankyrin repeat kinase (CARK), myoglobin (Myo), alpha cardiac actin (a-CARD), Troponin I (Tni), and Troponin T (Tnt), were compared to CMV promoter post retro orbital injection of 2.5x1010 viral particles of AAV6 or 9. In contrast to the previously reported heart biased signal seen in C57/B6 mice, signal was observed mainly in the liver of Balb/C mice. In vitro Luc activity, mRNA abundance and viral genomes (VG) assays were performed in liver and heart samples. Surprisingly, ∼10 folds higher Luc activity and RNA abundance in heart were observed for Tnt, Tni and a-CARD promoters than CMV promoter post AAV9 delivery, while a reduction of 100 fold was observed in liver. Copy number assay revealed six fold higher VG in liver than in heart for all promoters used including CMV. This indicates Tnt, Tni and a-CARD promoters have strong heart biased activity, without a tropism change as determined by VG copy numbers. To further develop the transcriptional targeting strategy three copies of mir122 binding site were inserted into the 3'UTR of AAV9-CMV-Luc and Balb/C mice were injected with 5x1010 viral particles. This resulted in ∼30 fold less Luc activity when compared to AAV9 without mir122 binding sites, with no change in VG copy number. In conclusion, in a mouse strain biased for liver expression after systemic delivery, transcriptional targeting to heart can be accomplished by using strong cardiac biased promoter integrated with mir122 binding sites in the 3’UTR.
Comorbid panic disorder in patients with winter depression
Authors: M T Halle, S C Dilsaver
Journal: American Journal of Psychiatry (1993)

This study investigated the prevalence of comorbid panic disorder in patients with recurrent wintertime episodes of major depression. The subjects were 38 patients (10 male and 28 female) who met the DSM-III-R criteria for major depression with a seasonal pattern (wintertime depression). Diagnoses of panic disorder were made according to the DSM-III-R criteria. Nine (23.7%) of the subjects (four women and five men) met the criteria for panic disorder. Their panic attacks and depressive symptoms had simultaneous onset in the fall or winter and remitted spontaneously in the spring. Patients with winter depression appear to be at high risk for simultaneous panic disorder, consistent with results from studies in which season of illness was not considered.
Abstract 9971: Comparison of Stents Coated with Antibody against CD34 versus Vascular Endothelial-Cadherin: Anti-VE-Cadherin-Antibody-Coated Stents are Better In Rapid Endothelialization and Reduction of Neointimal Formation
Authors: Joo Myung Lee, WonSeok Choe, Won-Woo Seo, Woo-Hyun Lim, Chan-Koo Kang, San Kyeong, Hyun-Ju Cho, Baek-Kyung Kim, Young-Chan Kim, Jin Hur, Han-Mo Yang, Kyung Woo Park, Hyun-Jai Cho, Yoon-Sik Lee, Hyo-Soo Kim
Journal: Circulation (2012)

Background Vascular endothelial-cadherin is exclusively expressed on the late endothelial progenitor cells. We evaluated whether anti-VE-cadherin antibody-coated stents might accelerate endothelial recovery and reduce neointimal formation more than anti-CD34 antibody-coated stents through the superior ability to capture the late EPC. Methods The BMS were coated with anti-VE-cadherin antibodies or anti-CD34 antibodies under the same condition. In vitro, the ability to capture EPC and specific cell capturing ability was evaluated. In vivo, re-endothelialization of stent in the rabbit iliac arteries was assessed by serial scanning electron microscopy. At 42 days, the area and proliferating activity of the neointima was compared between two stents. Results VE-cad stents showed higher number of adhering EPC (823.6 ± 182.2 versus 379.2 ± 137.2 cells/HPF, p&lt;0.001). VE-cad stents also demonstrated better specific capturing of cells with endothelial lineage markers than CD34 stents did in flow cytometric analysis. VE-cad stents showed more effective re-endothelialization after 3 days in vivo. At 42 days, VE-cad stents demonstrated significantly smaller neointima area (0.92 ± 0.38 versus 1.24 ± 0.41 mm 2 , p=0.002) and significantly lower PCNA positive cells in neointima (1684.8 ± 658.8/mm 2 versus 2681.7 ± 375.1/mm 2 , p=0.008), compared with CD34 stents. Conclusions VE-cad stents captured EPC and endothelial cells more selectively in vitro, accelerated re-endothelialization over stents, and reduced neointimal formation in vivo, compared with CD34 stents. Targeting the VE-cadherin could be more reasonable strategy in developing the next generation pro-healing stents.
PO14FACTORS EFFECTING SURVIVAL IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
Authors: Duncan Henderson, Anthony Chalmers, Mark White, Brian Clarke
Journal: Neuro-Oncology (2015)

INTRODUCTION: Glioblastoma multiforme (GBM) is a common intracranial tumour and carries a poor prognosis.The aim of this study was to identify prognostic factors of survival for patients diagnosed with GBM in the West of Scotland. METHOD: A retrospective study was carried out on all patients diagnosed with GBM in Glasgow between 2010-2012. Survival was defined as the number of days from the diagnostic surgery to death. Data was collected on age, WHO performance status, surgical resection, MGMT and IDH status, Temozolomide, radical and palliative radiotherapy, and medications at the time of diagnosis. Statistical analysis was carried out using SPSS. The Log rank test was used to generate p values and Kaplan-Meier graphs to display the data. RESULTS: The total sample size was 226. The median survival for patients aged  2 (p < 0.001). In patients who underwent radical radiotherapy, methylated MGMT was associated with a median survival of 747 days compared with 357 in unmethylated (p < 0.001). In patients who underwent palliative radiotherapy, methylation status was not associated with prolonged survival (p = 0.3).Within the radical radiotherapy subgroup (n = 110), there were 6 patients who were taking Metformin at the time of diagnosis. The median survival of these patients was 582 days compared with 453 in those not taking Metformin. Simvastatin usage did not correlate with survival. CONCLUSION: Age, WHO performance status, surgical resection and MGMT methylation in patients receiving radical radiotherapy are prognostic indicators of survival in GBM.
Pilot Study Identifies Obesity, Outdoor Air Pollution, and Tobacco Smoke Exposure As Contributors to High Estimated Prevalence of Risk of Asthma in Inner-City Schoolchildren from Pittsburgh Region
Authors: Tricia Morphew, Jennifer Paden Elliott, Paige E. Dewhirst, Nicole Pleskovic, Erica Butler, David P. Skoner, Deborah A. Gentile
Journal: Journal of Allergy and Clinical Immunology (2016)
<i>The BMJ</i>should not narrowly confine publication to positivist quantitative studies
Authors: Fiona Webster
Journal: BMJ (2016)

I am disappointed in the official response by the editors of The BMJ .1 2 I am fortunate enough to be a member of a community of research scientists who are largely trained in social science approaches, such as critical qualitative research, at the University of Toronto in Canada (Centre for Critical …
Indian medical council should be scrapped, says parliamentary committee
Authors: Ganapati Mudur
Journal: BMJ (2016)

An Indian parliamentary panel has urged the government to dismantle the Medical Council of India, saying that the organisation had consistently failed to regulate medical education and practice.

In a report, the parliamentary standing committee on health said that the regulatory body could no longer be entrusted with its responsibilities in view of its “massive failures.”1

The committee said that the council had failed to tackle gaps in medical education that left many doctors poorly equipped to manage even common illnesses. The panel also said that the council had not checked corruption during approvals …
Monitoring Circulating Tumor Cells (Ctc) in Lung Cancer: Preliminary Results
Authors: M.E. Olmedo, L. Mezquita, J. Earl, A. Benito, A. Santon, F. Longo, C. Vallejo, G. MuÑoz, L. Gorospe, A. Soria, T. Alonso Gordoa, E. Grande, E. Roberts, A. Gomez, P. Cortez, R. Alcalde, J. Muñoz, A. Cortés, A. Carrato, P. Garrido
Journal: Annals of Oncology (2014)
Molecular Pathways: Immunosuppressive Roles of IRE1α-XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment
Authors: Juan R. Cubillos-Ruiz, Sarah E. Bettigole, Laurie H. Glimcher
Journal: Clinical Cancer Research (2016)

Abstract The endoplasmic reticulum (ER) is a massive cytoplasmic membrane network that functions primarily to ensure proper folding and posttranslational modification of newly synthesized secreted and transmembrane proteins. Abnormal accumulation of unfolded proteins in this organelle causes a state of "ER stress," which is a hallmark feature of various diseases, including cancer, neurodegeneration, and metabolic dysfunction. Cancer cells exploit the IRE1α-XBP1 arm of the ER stress response to efficiently adjust their protein-folding capacity and ensure survival under hostile tumor microenvironmental conditions. However, we recently found that dendritic cells (DC) residing in the ovarian cancer microenvironment also experience sustained ER stress and demonstrate persistent activation of the IRE1α-XBP1 pathway. This previously unrecognized process disrupts metabolic homeostasis and antigen-presenting capacity in DCs, thereby crippling their natural ability to support the protective functions of infiltrating antitumor T cells. In this review, we briefly discuss some of the mechanisms that fuel ER stress in tumor-associated DCs, the biologic processes altered by aberrant IRE1α-XBP1 signaling in these innate immune cells, and the unique immunotherapeutic potential of targeting this pathway in cancer hosts. Clin Cancer Res; 22(9); 2121–6. ©2016 AACR.
PWE-138 Increasing burden of alcohol related brain injury is disproportionate to hospital admissions with liver disease
Authors: S Atkins, K Rackham, J Acevedo, JK Dowman, AJ Fowell, RJ Aspinall
Journal: Gut (2015)

<h3>Introduction</h3> Patients with alcohol related brain injury (ARBI) including Korsakoff’s syndrome frequently present to hospital with cognitive impairment, physical illness and consequences of greater risk-taking behaviour. We studied the impact of ARBI admissions on an acute hepatology unit and compared this with trends in hospitalisation for alcohol related liver disease over a 5 year period. <h3>Method</h3> We studied a large acute hospital serving a population of over 650,000 in the highest national quintile for both alcohol related admissions and cirrhosis deaths. We analysed hospital episode statistics and departmental databases for 5 consecutive financial years from 2009–2014, focusing on Korsakoff’s syndrome, specific liver disorders including complications of cirrhosis and alcohol related admissions in general. A cohort of frequently attending patients with ARBI were selected for detailed analysis of admission patterns and clinical outcomes. <h3>Results</h3> During the 5 years from 2009/10 to 2013/14, admissions with ARBI increased by over 120% (<i>p &lt; 0</i>.05) while annual bed days rose from 103 to a peak of 484, accounting for 1,351 bed days in total. Mean length of stay for ARBI increased by 56% overall. Some 64% of stays were for more than 14 days, 38% were over 28 days and 28% were over 42 days. However, admissions with alcohol related liver disease did not change substantially (<i>p</i>=NS) and, similarly, hospital-wide alcohol related admissions increased only marginally from 1,993 to 2,031 per 100,000 across the study period. Detailed case analysis found that 13 individuals (mean age 50 years, range 42–59) with Korsakoff’s syndrome accounted for over 90% of the ARBI bed days along with 297 ED attendances during the study, requiring a mean of 19.6 inpatient days per person per year. <h3>Conclusion</h3> Patients with Korsakoff’s syndrome pose significant clinical challenges with recurrent, prolonged admissions to hospital. Both the numbers of admissions and bed occupancy due to ARBI have substantially increased over the last 5 years, out of proportion to other markers of alcohol-related harm including acute and chronic liver disease. Further work may be needed to improve community and hospital care for these vulnerable individuals. <h3>Disclosure of interest</h3> None Declared.